Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 210

1.

The Cdk inhibitor flavopiridol enhances temozolomide-induced cytotoxicity in human glioma cells.

Hayashi T, Adachi K, Ohba S, Hirose Y.

J Neurooncol. 2013 Nov;115(2):169-78. doi: 10.1007/s11060-013-1220-5. Epub 2013 Aug 13.

PMID:
23943501
2.

Inhibition of c-Jun N-terminal kinase enhances temozolomide-induced cytotoxicity in human glioma cells.

Ohba S, Hirose Y, Kawase T, Sano H.

J Neurooncol. 2009 Dec;95(3):307-316. doi: 10.1007/s11060-009-9929-x. Epub 2009 Jun 11.

PMID:
19517066
4.
5.
6.

Cooperative function of Chk1 and p38 pathways in activating G2 arrest following exposure to temozolomide.

Hirose Y, Katayama M, Berger MS, Pieper RO.

J Neurosurg. 2004 Jun;100(6):1060-5.

PMID:
15200121
7.

Inhibition of 90-kD heat shock protein potentiates the cytotoxicity of chemotherapeutic agents in human glioma cells.

Ohba S, Hirose Y, Yoshida K, Yazaki T, Kawase T.

J Neurosurg. 2010 Jan;112(1):33-42. doi: 10.3171/2009.3.JNS081146.

PMID:
19408974
8.

Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine.

Roos WP, Batista LF, Naumann SC, Wick W, Weller M, Menck CF, Kaina B.

Oncogene. 2007 Jan 11;26(2):186-97. Epub 2006 Jul 3.

PMID:
16819506
9.

TMZ-induced PrPc/par-4 interaction promotes the survival of human glioma cells.

Zhuang D, Liu Y, Mao Y, Gao L, Zhang H, Luan S, Huang F, Li Q.

Int J Cancer. 2012 Jan 15;130(2):309-18. doi: 10.1002/ijc.25985. Epub 2011 May 30.

10.

Resveratrol abrogates the temozolomide-induced G2 arrest leading to mitotic catastrophe and reinforces the temozolomide-induced senescence in glioma cells.

Filippi-Chiela EC, Thomé MP, Bueno e Silva MM, Pelegrini AL, Ledur PF, Garicochea B, Zamin LL, Lenz G.

BMC Cancer. 2013 Mar 22;13:147. doi: 10.1186/1471-2407-13-147.

11.

Multifaceted resistance of gliomas to temozolomide.

Bocangel DB, Finkelstein S, Schold SC, Bhakat KK, Mitra S, Kokkinakis DM.

Clin Cancer Res. 2002 Aug;8(8):2725-34.

12.
13.
14.

Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma.

Blough MD, Beauchamp DC, Westgate MR, Kelly JJ, Cairncross JG.

J Neurooncol. 2011 Mar;102(1):1-7. doi: 10.1007/s11060-010-0283-9. Epub 2010 Jul 1.

PMID:
20593219
15.

N-methylpurine DNA glycosylase and DNA polymerase beta modulate BER inhibitor potentiation of glioma cells to temozolomide.

Tang JB, Svilar D, Trivedi RN, Wang XH, Goellner EM, Moore B, Hamilton RL, Banze LA, Brown AR, Sobol RW.

Neuro Oncol. 2011 May;13(5):471-86. doi: 10.1093/neuonc/nor011. Epub 2011 Mar 3.

17.

FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.

Wu Y, Dong L, Bao S, Wang M, Yun Y, Zhu R.

Biomed Pharmacother. 2016 Dec;84:462-469. doi: 10.1016/j.biopha.2016.09.051. Epub 2016 Sep 28.

PMID:
27685789
18.

The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents.

Chen CC, Taniguchi T, D'Andrea A.

J Mol Med (Berl). 2007 May;85(5):497-509. Epub 2007 Jan 13.

PMID:
17221219
19.

ATM inhibitor KU-55933 increases the TMZ responsiveness of only inherently TMZ sensitive GBM cells.

Nadkarni A, Shrivastav M, Mladek AC, Schwingler PM, Grogan PT, Chen J, Sarkaria JN.

J Neurooncol. 2012 Dec;110(3):349-57. doi: 10.1007/s11060-012-0979-0. Epub 2012 Oct 3.

20.

Inhibition of Aurora-B function increases formation of multinucleated cells in p53 gene deficient cells and enhances anti-tumor effect of temozolomide in human glioma cells.

Tsuno T, Natsume A, Katsumata S, Mizuno M, Fujita M, Osawa H, Nakahara N, Wakabayashi T, Satoh Y, Inagaki M, Yoshida J.

J Neurooncol. 2007 Jul;83(3):249-58. Epub 2007 Feb 14.

PMID:
17570035

Supplemental Content

Support Center